José Valentín
García Gutiérrez
Profesor/a Asociado/a en CC. de la Salud
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (9)
2023
2022
-
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
Journal of Hematology and Oncology, Vol. 15, Núm. 1
-
CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S295-S296
-
MPN-141 Retrospective Comparison of Patient Outcomes on Pacritinib Versus Ruxolitinib in Patients With Myelofibrosis and Thrombocytopenia
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S326-S327
2021
-
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Blood, Vol. 138, Núm. 21, pp. 2031-2041
2020
-
Determining the recommended dose of pacritinib: Results from the PAC203 dose-finding trial in advanced myelofibrosis
Blood Advances, Vol. 4, Núm. 22, pp. 5825-5835
2019
-
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia
Journal of Cancer Research and Clinical Oncology, Vol. 145, Núm. 6, pp. 1589-1599
2018
-
Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial
Journal of Clinical Oncology, Vol. 36, Núm. 3, pp. 231-237
2010
-
Characteristics of pericardial effusions in patients with leukemia
Cancer, Vol. 116, Núm. 10, pp. 2366-2371